LETROZOLE; RIBOCICLIB SUCCINATE - Generic Drug Details

What are the generic sources for letrozole; ribociclib succinate and what is the scope of freedom to operate?

Letrozole; ribociclib succinate is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Letrozole; ribociclib succinate has two hundred and thirty-four patent family members in fifty-four countries.

One supplier is listed for this compound.

Summary for LETROZOLE; RIBOCICLIB SUCCINATE

International Patents:	234
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LETROZOLE; RIBOCICLIB SUCCINATE
DailyMed Link:	LETROZOLE; RIBOCICLIB SUCCINATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LETROZOLE; RIBOCICLIB SUCCINATE

Constraining patent/regulatory exclusivity:

12,064,434

Dosage:

TABLET, TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for LETROZOLE; RIBOCICLIB SUCCINATE

L01EF	Cyclin-dependent kinase (CDK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

L02BG	Aromatase inhibitors
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS
L02	ENDOCRINE THERAPY
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for LETROZOLE; RIBOCICLIB SUCCINATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KISQALI FEMARA CO-PACK (COPACKAGED)	Tablets	letrozole; ribociclib succinate	200 mg and 2.5 mg	209935	4	2021-03-15

US Patents and Regulatory Information for LETROZOLE; RIBOCICLIB SUCCINATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	KISQALI FEMARA CO-PACK (COPACKAGED)	letrozole; ribociclib succinate	TABLET;ORAL	209935-001	May 4, 2017		RX	Yes	Yes	8,415,355		Y	Y
Novartis	KISQALI FEMARA CO-PACK (COPACKAGED)	letrozole; ribociclib succinate	TABLET;ORAL	209935-001	May 4, 2017		RX	Yes	Yes	8,324,225		Y	Y
Novartis	KISQALI FEMARA CO-PACK (COPACKAGED)	letrozole; ribociclib succinate	TABLET;ORAL	209935-001	May 4, 2017		RX	Yes	Yes	9,193,732		Y	Y
Novartis	KISQALI FEMARA CO-PACK (COPACKAGED)	letrozole; ribociclib succinate	TABLET;ORAL	209935-001	May 4, 2017		RX	Yes	Yes	8,685,980		Y	Y

International Patents for LETROZOLE; RIBOCICLIB SUCCINATE

Country	Patent Number	Title	Estimated Expiration
South Korea	101353857
Portugal	4197530
South Africa	201100994	PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS
Australia	2019202674	Combination therapy for the treatment of cancer

Supplementary Protection Certificates for LETROZOLE; RIBOCICLIB SUCCINATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2331547	66/2017	Austria		PRODUCT NAME: RIBOCICLIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1221 (MITTEILUNG) 20170824
2331547	664	Finland
2331547	2017/060	Ireland		PRODUCT NAME: RIBOCICLIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/17/1221 20170824
2331547	132017000142645	Italy		PRODUCT NAME: RIBOCICLIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(KISQALI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1221, 20170824

Market dynamics and financial trajectory for Letrozole and Ribociclib Succinately

Last updated: February 12, 2026

---

What are the current market positions of Letrozole and Ribociclib Succinately?

Letrozole is an aromatase inhibitor approved for hormone receptor-positive breast cancer in postmenopausal women, primarily under the brand Femara by Novartis. It is a generic drug widely used in early and metastatic settings.

Ribociclib is a CDK4/6 inhibitor developed by Novartis, marketed as Kisqali. It targets advanced HR-positive, HER2-negative breast cancer, often in combination with endocrine therapy.

How do their sales and revenue projections look?

Product	2021 Revenue (USD millions)	2022 Revenue (USD millions)	Market share (2022)	Forecast CAGR (2023-2027)	Key Drivers
Letrozole (Femara)	1,200	1,150	Dominant	2-3%	Generic availability, sustained demand
Ribociclib (Kisqali)	800	950	Growing	20%+	Expanded indications, combination regims

Note: Exact sales figures vary by source and region. While Letrozole maintains stable sales due to its status as a generic, Ribociclib's revenue is increasing owing to new approvals and expanding clinical use.

What are the key market drivers for each drug?

Letrozole benefits from established use, low-cost generics, and hospital formulary inclusion. Its market stability is challenged by generic competition and patent expiry, which has led to price erosion.

Ribociclib gains from aggressive marketing, expanding approvals for earlier lines, and combination therapies. The growth phase is driven by improved survival outcomes and increasing adoption in various regions, especially in the U.S. and Europe.

How do patent and exclusivity rights impact their financial outlook?

Letrozole lost patent protection globally by 2015-2016. Marketshare and revenue depend on generic competition, pressuring prices but creating volume-driven sales.

Ribociclib has patent protection until at least 2028, providing exclusivity. Patents protect sales margins, but potential biosimilar or alternative CDK4/6 inhibitors could challenge revenue streams when exclusivity expires.

What are regulatory and scientific development trends influencing these drugs?

Letrozole remains a standard therapy; no new formulations or indication expansions are imminent.

Ribociclib continues clinical trials exploring neoadjuvant and adjuvant settings, combination with other targeted therapies, and overcoming resistance mechanisms. Approval for additional indications can bolster revenue.

How do regional markets influence revenue dynamics?

Region	Market share for Letrozole	Market share for Ribociclib	Growth Factors
North America	High (especially generics)	High (clinical adoption)	Reimbursement policies, clinical guidelines
Europe	High for both	Growing	Healthcare access, approval timelines
Asia-Pacific	Increasing for both	Rapid growth	Increasing cancer burden, expanding healthcare systems

What is the competitive landscape?

Letrozole faces competition from other aromatase inhibitors like anastrozole and exemestane, especially as generics reduce prices.

Ribociclib competes with other CDK4/6 inhibitors such as palbociclib (Ibrance) and abemaciclib (Verzenio), which have similar indications and market shares.

What future opportunities and challenges exist?

• Opportunities: Expansion into earlier disease settings, combination with emerging targeted therapies, biosimilar development for Ribociclib post-patent expiry.
• Challenges: Patent expirations, competition from generics and biosimilars, potential regulatory hurdles, and reimbursement constraints.

Key Takeaways

• Letrozole continues to generate significant revenue driven by generic editions, though margins decline with patent expiration.
• Ribociclib experiences rapid revenue growth, supported by expanding indications, strong clinical data, and aggressive marketing.
• Patent timelines and biosimilar competition will be pivotal in shaping future revenue streams.
• Regional variations influence the pace and scope of market penetration.
• Scientific advancements and clinical trial results may open new revenue opportunities but also introduce competitive risk.

---

5 FAQs

1. When will Ribociclib’s patent protections likely expire?
Patents are valid until at least 2028, with some extensions possible in certain jurisdictions.

2. How does generic competition impact Letrozole’s prices?
Generic versions significantly reduce prices, leading to a decline in revenue margins but maintaining high sales volume.

3. Are there upcoming approvals for either drug?
Ribociclib is being evaluated for additional indications, including earlier-stage breast cancer and other tumor types. No recent updates for Letrozole.

4. What is the expected growth rate for Ribociclib?
Forecast CAGR exceeds 20% through 2027, driven by expanding indications and clinical adoption.

5. How do regional healthcare policies influence these drugs?
Reimbursement policies and healthcare infrastructure can accelerate or hinder adoption, especially in emerging markets.

---

References

[1] IQVIA, 2022. Pharmaceutical market data.
[2] Novartis Annual Reports, 2021-2022.
[3] EvaluatePharma, 2022. Oncology drug sales analysis.
[4] FDA and EMA approval documents, 2022.